Ildong signs antibody deal with US firm

Published: 2012-11-19 06:56:00

Updated: 2012-11-19 06:56:00

Ildong Pharmaceutical said Thursday it has signed an exclusive licensing agreement with the U.S. based TG Therapeutics Inc. for the development and commercialization of the company's novel anti-CD20 antibody, Ublituximab (TGTX-1101) in Korea and seven countries in Southeast Asia.

Under the dea...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK